Global CAR-T Cell Therapy Market Outlook, 2031

The global CAR-T cell therapy industry covers treatments in which a patient's or donor's T cells are genetically engineered to express a chimeric antigen receptor that recognises a target on diseased cells, then infused back to attack those cells. All approved products are autologous, made from the patient's own cells collected by leukapheresis, engineered and expanded in centralised facilities and returned after lymphodepleting chemotherapy. Approved therapies in the United States and Europe include Novartis's Kymriah, Gilead's Kite unit's Yescarta and Tecartus, Bristol Myers Squibb's Breyanzi and Abecma, Johnson & Johnson and Legend Biotech's Carvykti, and Autolus's Aucatzyl, approved in November 2024, while China has approved several domestic products from Fosun Kite, JW Therapeutics, CARsgen, IASO Bio and others. CAR-T therapies target CD19 in B-cell lymphomas and leukaemias and BCMA in multiple myeloma, producing long-lasting remissions in patients who have exhausted other options. The industry also includes contract manufacturers such as Lonza and Cellares, viral vector suppliers, automation companies such as Miltenyi Biotec and Cytiva, and specialist treatment centres, and it is attracting large investment into allogeneic, solid tumour, autoimmune and in vivo approaches.

CAR-T therapy has moved from last-resort treatment toward earlier use while facing manufacturing, access and safety challenges. Carvykti and Abecma were approved for earlier lines of multiple myeloma in 2024, and Breyanzi gained approvals in chronic lymphocytic leukaemia, follicular lymphoma and mantle cell lymphoma. The FDA added boxed warnings about secondary T-cell cancers to all CAR-T products in 2024, then in June 2025 removed the risk evaluation and mitigation strategies for approved autologous CAR-T therapies and eased requirements for patients to stay near treatment centres, aiming to widen access. Sales have grown strongly, but only a minority of eligible patients receive CAR-T because of cost, complex logistics and limited centres, and competition from bispecific antibodies has intensified. The most important recent shift is toward in vivo CAR-T, in which a single infusion instructs T cells inside the body to become CAR-T cells, removing personalised manufacturing. Pharmaceutical companies have raced to acquire this capability: AbbVie bought Capstan Therapeutics for USD 2.1 billion in July 2025, Bristol Myers Squibb bought Orbital Therapeutics for USD 1.5 billion in October 2025, Eli Lilly acquired Orna Therapeutics for up to USD 2.4 billion in February 2026 and agreed to buy Kelonia Therapeutics for up to USD 7 billion in April 2026. In February 2026, Gilead agreed to acquire Arcellx for USD 7.8 billion to secure anito-cel, a BCMA CAR-T with a US decision expected in December 2026. CAR-T therapy for autoimmune disease, including lupus and myositis, has also become a major development area.

Market Dynamics Market Drivers • Durable Remissions in Blood CancersCAR-T therapies produce deep and often long-lasting remissions in patients with relapsed or refractory large B-cell lymphoma, acute lymphoblastic leukaemia, follicular lymphoma, mantle cell lymphoma and multiple myeloma, including some who appear cured. Randomised trials have shown advantages over standard care in earlier lines of treatment, leading to label expansions and greater use. The rising incidence of blood cancers in ageing populations supports demand.
• Expansion into Autoimmune Disease and New FormatsCD19 and BCMA CAR-T therapies have produced drug-free remissions in small studies of lupus, myositis, systemic sclerosis and other autoimmune diseases, opening potentially large new markets. Allogeneic off-the-shelf CAR-T, dual-target CAR-T, armoured CAR-T for solid tumours and in vivo CAR-T are attracting large investment, and multibillion-dollar acquisitions since 2025 show strong pharmaceutical interest.

Market Challenges • Manufacturing Complexity, Cost and AccessAutologous CAR-T requires patient-specific manufacturing that takes weeks, involves viral vectors and strict quality controls, and costs several hundred thousand dollars per patient before hospital costs. Some patients deteriorate while waiting, and manufacturing failures occur. Only certified centres can administer therapy, and many eligible patients, particularly outside major cities and in lower-income countries, never receive it.
• Safety Risks and Competition from BispecificsCAR-T therapies can cause cytokine release syndrome, neurotoxicity, prolonged low blood counts, infections and, rarely, secondary T-cell cancers, which require specialist management. Bispecific T-cell engaging antibodies, which are available off the shelf and can be given in community settings, compete for the same patients in lymphoma and myeloma, pressuring CAR-T market share.

Market Trends • In Vivo CAR-T and Off-the-Shelf ApproachesIn vivo CAR-T uses lentiviral vectors or lipid nanoparticles carrying RNA to program T cells inside the body, potentially offering one-time treatment without leukapheresis or custom manufacturing. Companies including Kelonia, Capstan, Orbital, Orna, Interius, Umoja and many Chinese developers have begun clinical trials, and large pharmaceutical groups have acquired several of them. Allogeneic CAR-T from healthy donor cells also aims to reduce cost and delay.
• Faster Manufacturing and Community DeliveryCompanies are shortening vein-to-vein time through rapid manufacturing processes, automated closed systems and decentralised production at or near hospitals. Regulatory changes in 2025 reduced monitoring and travel requirements, and outpatient administration is increasing. These changes aim to bring CAR-T to more patients, including in community cancer centres and emerging markets.



Segment Analysis CD19-targeted CAR-T therapies account for the largest number of treated patients, while BCMA-targeted CAR-T therapies for multiple myeloma have become the largest revenue segment and the fastest-growing target. CD19-targeted CAR-T therapies, including Yescarta, Kymriah, Breyanzi, Tecartus and Aucatzyl, treat large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukaemia and acute lymphoblastic leukaemia, and they account for the largest cumulative number of patients. Yescarta and Breyanzi lead in lymphoma, where CAR-T is used in second-line treatment for early-relapsing patients. BCMA-targeted CAR-T therapies, including Carvykti and Abecma, treat multiple myeloma, and Carvykti has become the best-selling CAR-T product after strong results and approval in earlier lines. Anito-cel, under FDA review, would add another BCMA option. Other targets, such as CD22, GPRC5D, CD20 and CD7, are in development for blood cancers, often in dual-target designs to prevent relapse. Solid tumour targets, including GPC3, claudin 18.2, mesothelin, GD2 and B7-H3, are being studied, with some early successes in neuroblastoma and gastrointestinal cancers in China. Autoimmune targets focus mainly on CD19 and BCMA to deplete B cells and plasma cells. Target choice affects both efficacy and toxicity.

Autologous CAR-T therapies account for all current commercial revenue, while allogeneic and in vivo approaches represent the main sources of future growth. Autologous CAR-T therapies are made from each patient's own T cells, which avoids immune rejection and graft-versus-host disease but requires individual manufacturing and scheduling, and all approved products use this approach. Manufacturing improvements have reduced turnaround times and failure rates. Allogeneic CAR-T therapies use T cells from healthy donors or induced pluripotent stem cells, edited to reduce rejection, and can be manufactured in large batches and stored ready for use, although durability of response has lagged autologous products; companies such as Allogene, Caribou, CRISPR Therapeutics and Fate are developing them. In vivo CAR-T therapies deliver genetic instructions directly into patients using targeted lentiviral vectors or lipid nanoparticles, and early clinical data in myeloma and autoimmune disease have attracted multibillion-dollar acquisitions. Other engineered immune cell formats, including CAR-NK, CAR-macrophage and gamma-delta T cells, form adjacent segments. Viral vectors, mainly lentiviral and gamma-retroviral, remain the standard for gene transfer, while non-viral methods using transposons or CRISPR knock-in are growing.

Haematological malignancies account for almost all current CAR-T use, while autoimmune diseases and solid tumours represent the largest potential new indications. Large B-cell lymphoma, including diffuse large B-cell lymphoma, is the largest CAR-T indication by number of patients, with Yescarta and Breyanzi approved in second-line and later settings. Multiple myeloma has become the largest indication by revenue, driven by Carvykti's approval in earlier lines and strong efficacy. Acute lymphoblastic leukaemia in children and adults, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukaemia are further approved indications. Autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, myositis, systemic sclerosis, myasthenia gravis, multiple sclerosis and ANCA-associated vasculitis, are a major new focus, with dozens of trials in the United States, Europe and China. Solid tumours, including liver, gastric, pancreatic, brain and ovarian cancers and neuroblastoma, remain challenging because of antigen heterogeneity and the immunosuppressive tumour environment, but research is active. Other blood cancers, including acute myeloid leukaemia and T-cell lymphomas, lack safe targets and are areas of development. Infectious and fibrotic diseases are early research areas.

Hospitals and certified cancer centres are the main end users of CAR-T therapy, while community cancer centres and outpatient settings are gaining importance. Academic medical centres and large hospitals with bone marrow transplant programmes administer most CAR-T therapy, because they have the expertise to manage leukapheresis, lymphodepletion, infusion and complications such as cytokine release syndrome and neurotoxicity. Manufacturers certify these centres, and there are several hundred in the United States and Europe. Specialised cancer centres, including comprehensive cancer centres and dedicated cell therapy units, form another major group. Community oncology practices and outpatient infusion centres have begun administering CAR-T, particularly products with lower toxicity, supported by relaxed monitoring requirements since 2025. Contract manufacturing organisations produce CAR-T for developers and increasingly offer decentralised manufacturing. In China, hospitals conduct many investigator-initiated trials and commercial treatments. Payers, including Medicare in the United States and national health systems, influence use through reimbursement for the therapy and hospital stay, and outcomes-based agreements have been used in some countries. Specialty logistics companies transport cells under cryogenic conditions between hospitals and manufacturing sites.

Regional Analysis North America leads the CAR-T cell therapy market because of early approvals, high prices, broad reimbursement and the concentration of developers, while China is the fastest-growing market and a global leader in CAR-T clinical development. North America, led by the United States, accounts for the largest share of CAR-T revenue. All major Western CAR-T products were first approved in the United States, where Medicare and commercial insurers cover therapy, and US companies lead in allogeneic and in vivo CAR-T development. The FDA's removal of CAR-T REMS requirements in June 2025, Gilead's agreement to buy Arcellx in February 2026 and Lilly's acquisitions of Orna and Kelonia in 2026 show continued investment. Europe is the second largest market, with approved CAR-T products available in most countries, strong academic programmes such as those in Germany that pioneered CAR-T in lupus, and point-of-care manufacturing in Spain and elsewhere, although pricing negotiations limit access in some countries. China is the fastest-growing market and has more CAR-T clinical trials than any other country, several approved domestic products at lower prices than Western therapies, and leading work in in vivo, autoimmune and solid tumour CAR-T. Legend Biotech, the developer of Carvykti, originated in China. Japan, South Korea, Australia and Singapore have approved CAR-T therapies and growing programmes. India approved its first domestic CAR-T therapy, NexCAR19, in 2023 at a much lower price, and Brazil and the Middle East are building capacity. Latin America and Africa have limited access.

Key Developments April 2026: Lilly agreed to buy Kelonia for up to USD 7 billion, gaining an in vivo CAR-T platform whose lead BCMA programme is in phase 1 for multiple myeloma.
February 2026: Gilead agreed to acquire Arcellx for USD 7.8 billion to secure anito-cel, a BCMA-directed CAR-T therapy with a US decision date of December 2026.
February 2026: Lilly agreed to acquire Orna Therapeutics for up to USD 2.4 billion, adding circular RNA and lipid nanoparticle technology for in vivo CAR-T.
October 2025: Bristol Myers Squibb agreed to buy Orbital Therapeutics for USD 1.5 billion to gain RNA-based in vivo CAR-T therapies.
July 2025: AbbVie agreed to buy Capstan for up to USD 2.1 billion, gaining an in vivo CAR-T candidate for B-cell-driven autoimmune diseases.
June 2025: The FDA eliminated risk evaluation and mitigation strategies for approved autologous CAR-T products and reduced post-infusion proximity and driving restrictions to improve access.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global CAR-T Cell Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Target Antigen
• CD19
• BCMA
• Other Haematological Targets
• Solid Tumour Targets

By Therapy Type
• Autologous CAR-T
• Allogeneic CAR-T
• In Vivo CAR-T

By Indication
• Large B-Cell Lymphoma
• Multiple Myeloma
• Acute Lymphoblastic Leukaemia
• Other B-Cell Malignancies
• Autoimmune Diseases
• Solid Tumours

By End User
• Hospitals and Academic Medical Centres
• Specialised Cancer Centres
• Community Oncology Centres